Beyond the Antagonism: Self-Labeled Xanthone Inhibitors as Modeled “Two-in-One” Drugs in Cancer Therapy

[Image: see text] Self-labeled inhibitors (SLIs) are promising for creating links, ranging from cancer therapy and metastatic pathways to mechanistic elucidation. In this study, a new category of “two-in-one” fluorescent xanthone inhibitors was developed for the systematic evaluation of anticancer a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Fu-Chao, Lin, Xin-Rong, Liu, Zhi-Cheng, Zhang, Ji-Hong, Liu, Fei-Fei, Wu, Wei, Ma, Yu-Lu, Qu, Wen-Wen, Yan, Sheng-Jiao, Lin, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044579/
https://www.ncbi.nlm.nih.gov/pubmed/30023617
http://dx.doi.org/10.1021/acsomega.6b00545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044579/
https://www.ncbi.nlm.nih.gov/pubmed/30023617
http://dx.doi.org/10.1021/acsomega.6b00545

Ejemplares similares